Original Article
Compare therapeutic effects and adverse effects between TEC-NX regime and TEC regime in adjuvant chemotherapy of local advanced breast cancer patients
Zhiwei Wang, Min Wei, Jie Wang, Li Yang, Yuguo Shao, Min Ji, Qi He
Published 2019-05-15
Cite as Int J Surg, 2019, 46(5): 325-329,f3. DOI: 10.3760/cma.j.issn.1673-4203.2019.05.009
Abstract
ObjectiveTo compare the difference of efficacy and adverse effects between TEC-NX regimen (Docetaxel + Epirubicin + Cyclophosphamide sequential Vinorelbine + Capecitabine) with TEC regimen (Docetaxel + Epirubicin + Cyclophosphamide) in the adjuvant chemotherapy of locally advanced breast cancer.
MethodsA retrospective study was conducted to select 58 patients with locally advanced breast cancer who underwent ≥4 axillary lymph node metastasis from April 2008 to April 2015 at the International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine. All patients were female, average age was 48 years old, rang from 29 to 63 years old. Patients were divided into TEC-NX group (n=23) and TEC group (n=35) according to different treatment methods. TEC-NX group patients received chemotherapy with TEC-NX regimen and TEC group patients received chemotherapy with TEC regimen. The 3-year overall survival rate and 3-year disease-free survival rate were compared between the two groups. The differences in adverse reactions such as myelosuppression, liver dysfunction and fever were compared between the two groups. The Chi-square test was used to compare the count data between the two groups; the survival analysis was performed by Kaplan-Meier method.
ResultsThe 3-year overall survival rate was 91.3% in the TEC-NX group and 91.4% in the TEC group, and the difference was not statistically significant (P=0.995). The 3-year disease-free survival rate was 73.9% in the TEC-NX group and 85.7% in the TEC group, and the difference was not statistically significant (P=0.289). The incidence of grade Ⅲ or Ⅳ myelosuppression in the TEC-NX group was 26.0%, which was significantly lower than that in the TEC group (65.7%), and the difference was statistically significant (P=0.009). The incidence of liver dysfunction was 91.3% in the TEC-NX group, and there was not statistically significant compared with 93.5% in the TEC group (P=0.523). The incidence of fever in the TEC-NX group was 17.4%, which was not statistically significant compared with the TEC group (14.3%) (P=0.749).
ConclusionIn adjuvant chemotherapy for locally advanced breast cancer, the TEC-NX regimen does not improve 3-year overall survival and disease-free survival compared with the TEC regimen, but the TEC-NX regimen significantly reduced the incidence of grade Ⅲ or Ⅳ myelosuppression.
Key words:
Breast neoplasms; Antineoplastic combined chemotherapy protocols; Vinorelbine; Capecitabine; Therapeutic uses; Adverse effects
Contributor Information
Zhiwei Wang
Department of Breast, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
Min Wei
Jie Wang
Li Yang
Yuguo Shao
Min Ji
Qi He
